DPS is routinely engaged in early-stage site selection discussions with our clients and prospective clients in response to the recent growth in RNA manufacturing due to the COVID-19 virus. Throughout these evaluations, we have gained unique insight into the requirements including site selection and design for RNA manufacturing facilities.
Read DPS Group’s Jeffrey Heil’s article to understand key points of consideration when planning for your RNA manufacturing facility.
You may be interested in